{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:28:50Z","timestamp":1792024130779,"version":"4.4.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This paper aims to examine the latest research on treatments for itch (pruritus) in people with systemic sclerosis (SSc), identify areas where information is lacking, and propose suggestions for future studies.A comprehensive literature search was performed in PubMed and Scopus in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines to identify studies evaluating therapeutic interventions for pruritus in SSc. Eligible studies included randomized controlled trials, cohort studies, and case series comprising a minimum of three patients. Data extraction encompassed study design, patient demographics, pruritus assessment instruments including validated and non-validated measures, and clinical outcomes. Studies were excluded if they concerned localized scleroderma, irrelevant populations, case reports, systematic reviews, lacking relevant outcome data, or incomplete trials. Ten studies met criteria, evaluating immunomodulatory agents, mast cell stabilizers, opioid receptor antagonist, and lysophosphatidic acid receptor antagonists. Pruritus assessment varied and was often secondary to fibrosis outcomes. Oral lenabasum improved pruritus in a phase II trial; low-dose opioid receptor modulators and rituximab also showed qualitative improvement. Pruritus is a frequently overlooked yet clinically significant symptom in systemic sclerosis (SSc) that negatively impacts patients\u2019 quality of life. Existing evidence regarding effective therapeutic options remains limited. Future research should prioritize pruritus as a predefined outcome and utilize validated assessment instruments to inform treatment strategies and enhance patient quality of life.<\/jats:p>","DOI":"10.1007\/s00296-026-06190-5","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T08:13:04Z","timestamp":1782115984000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pruritus associated with systemic sclerosis: a systematic review of treatment-based clinical trials"],"prefix":"10.1007","volume":"46","author":[{"given":"Kiana","family":"Mortezaei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4711-5453","authenticated-orcid":false,"given":"Rishika","family":"Pasula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7164-9592","authenticated-orcid":false,"given":"Meryem","family":"Nursoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2514-5316","authenticated-orcid":false,"given":"Amit","family":"Syal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Panayiotou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7221-5807","authenticated-orcid":false,"given":"Geeta","family":"Kumari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6635-9564","authenticated-orcid":false,"given":"Andreas","family":"Chatzitoffis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavle","family":"Milutinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3835-697X","authenticated-orcid":false,"given":"Olajumoke O.","family":"Fadugba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7786-9714","authenticated-orcid":false,"given":"Chris T.","family":"Derk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"6190_CR1","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.3389\/fimmu.2019.01303","volume":"10","author":"C Zeidler","year":"2019","unstructured":"Zeidler C, Pereira MP, Huet F, Misery L, Steinbrink K, St\u00e4nder S (2019) Pruritus in autoimmune and inflammatory dermatoses. Front Immunol 10:1303. https:\/\/doi.org\/10.3389\/fimmu.2019.01303","journal-title":"Front Immunol"},{"issue":"8","key":"6190_CR2","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1111\/jdv.19913","volume":"38","author":"C Zeidler","year":"2024","unstructured":"Zeidler C, Kupfer J, Dalgard FJ, Bewley A, Evers AWM, Gieler U et al (2024) Dermatological patients with itch report more stress, stigmatization experience, anxiety and depression compared to patients without itch: Results from a European multi-centre study. J Eur Acad Dermatol Venereol 38(8):1649\u20131661. https:\/\/doi.org\/10.1111\/jdv.19913","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"6190_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.2340\/00015555-3346","volume":"100","author":"R Reszke","year":"2020","unstructured":"Reszke R, Szepietowski J (2020) Itch and Psyche: bilateral associations. Acta Derm Venereol 100(2):28\u201336. https:\/\/doi.org\/10.2340\/00015555-3346","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"6190_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1038\/s41398-018-0097-7","volume":"8","author":"L Misery","year":"2018","unstructured":"Misery L, Dutray S, Chastaing M, Schollhammer M, Consoli SG, Consoli SM (2018) Psychogenic itch. Transl Psychiatry 8(1):52. https:\/\/doi.org\/10.1038\/s41398-018-0097-7","journal-title":"Transl Psychiatry"},{"issue":"12","key":"6190_CR5","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1111\/exd.13992","volume":"28","author":"AWM Evers","year":"2019","unstructured":"Evers AWM, Peerdeman KJ, Van Laarhoven AIM (2019) What is new in the psychology of chronic itch? Exp Dermatol 28(12):1442\u20131447. https:\/\/doi.org\/10.1111\/exd.13992","journal-title":"Exp Dermatol"},{"key":"6190_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/9625936","volume":"2018","author":"J Song","year":"2018","unstructured":"Song J, Xian D, Yang L, Xiong X, Lai R, Zhong J (2018) Pruritus: Progress toward Pathogenesis and Treatment. BioMed Res Int 2018:1\u201312. https:\/\/doi.org\/10.1155\/2018\/9625936","journal-title":"BioMed Res Int"},{"issue":"8","key":"6190_CR7","doi-asserted-by":"publisher","first-page":"735","DOI":"10.2340\/00015555-2980","volume":"98","author":"G Gourier","year":"2018","unstructured":"Gourier G, Th\u00e9r\u00e9n\u00e9 C, Mazeas M, Abasq-Thomas C, Brenaut E, Huet F et al (2018) Clinical Characteristics of Pruritus in Systemic Sclerosis Vary According to the Autoimmune Subtype. Acta Derm Venereol 98(8):735\u2013741. https:\/\/doi.org\/10.2340\/00015555-2980","journal-title":"Acta Derm Venereol"},{"issue":"2 Suppl 76","key":"6190_CR8","first-page":"81","volume":"31","author":"TM Frech","year":"2013","unstructured":"Frech TM, Baron M (2013) Understanding itch in systemic sclerosis in order to improve patient quality of life. Clin Exp Rheumatol 31(2 Suppl 76):81\u201388 PubMed PMID: 23910614","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"6190_CR9","doi-asserted-by":"publisher","first-page":"e28653","DOI":"10.1097\/MD.0000000000028653","volume":"101","author":"K Meridor","year":"2022","unstructured":"Meridor K, Berookhim J, Levy Y (2022) Low dose naloxone for pruritus in systemic sclerosis: Case series and literature review. Med (Baltim) 101(4):e28653. https:\/\/doi.org\/10.1097\/MD.0000000000028653","journal-title":"Med (Baltim)"},{"issue":"1","key":"6190_CR10","doi-asserted-by":"publisher","first-page":"5947","DOI":"10.1038\/s41467-021-26099-w","volume":"12","author":"A Kuzumi","year":"2021","unstructured":"Kuzumi A, Yoshizaki A, Matsuda KM, Kotani H, Norimatsu Y, Fukayama M et al (2021) Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis. Nat Commun 12(1):5947. https:\/\/doi.org\/10.1038\/s41467-021-26099-w","journal-title":"Nat Commun"},{"key":"6190_CR11","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ n71. https:\/\/doi.org\/10.1136\/bmj.n71","DOI":"10.1136\/bmj.n71"},{"issue":"3","key":"6190_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/XEB.0000000000000064","volume":"13","author":"S Moola","year":"2015","unstructured":"Moola S, Munn Z, Sears K, Sfetcu R, Currie M, Lisy K et al (2015) Conducting systematic reviews of association (etiology): The Joanna Briggs Institute\u2019s approach. Int J Evid Based Healthc 13(3):163\u2013169. https:\/\/doi.org\/10.1097\/XEB.0000000000000064","journal-title":"Int J Evid Based Healthc"},{"key":"6190_CR13","doi-asserted-by":"publisher","unstructured":"Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A et al Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Database Syst Rev Implement Rep. 2019;Publish Ahead of Print. https:\/\/doi.org\/10.11124\/JBISRIR-D-19-00099","DOI":"10.11124\/JBISRIR-D-19-00099"},{"issue":"8","key":"6190_CR14","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1002\/art.41294","volume":"72","author":"R Spiera","year":"2020","unstructured":"Spiera R, Hummers L, Chung L, Frech TM, Domsic R, Hsu V et al (2020) Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo-Controlled Trial in Adults With Systemic Sclerosis. Arthritis Rheumatol 72(8):1350\u20131360. https:\/\/doi.org\/10.1002\/art.41294","journal-title":"Arthritis Rheumatol"},{"issue":"11","key":"6190_CR15","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.autrev.2015.07.008","volume":"14","author":"D Giuggioli","year":"2015","unstructured":"Giuggioli D, Lumetti F, Colaci M, Fallahi P, Antonelli A, Ferri C (2015) Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. Autoimmun Rev 14(11):1072\u20131078. https:\/\/doi.org\/10.1016\/j.autrev.2015.07.008","journal-title":"Autoimmun Rev"},{"issue":"10","key":"6190_CR16","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1111\/j.1365-4362.1995.tb04664.x","volume":"34","author":"BS Pai","year":"1995","unstructured":"Pai BS, Srinivas CR, Sabitha L, Shenoi SD, Balachandran CN, Acharya S, EFFICACY OF DEXAMETHASONE PULSE THERAPY IN PROGRESSIVE SYSTEMIC SCLEROSIS (1995) Int J Dermatol 34(10):726\u2013728. https:\/\/doi.org\/10.1111\/j.1365-4362.1995.tb04664.x","journal-title":"Int J Dermatol"},{"issue":"10","key":"6190_CR17","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/art.40547","volume":"70","author":"Y Allanore","year":"2018","unstructured":"Allanore Y, Distler O, Jagerschmidt A, Illiano S, Ledein L, Boitier E et al (2018) Lysophosphatidic Acid Receptor 1 Antagonist SAR100842 for Patients With Diffuse Cutaneous Systemic Sclerosis: A Double-Blind, Randomized, Eight\u2010Week Placebo\u2010Controlled Study Followed by a Sixteen\u2010Week Open\u2010Label Extension Study. Arthritis Rheumatol 70(10):1634\u20131643. https:\/\/doi.org\/10.1002\/art.40547","journal-title":"Arthritis Rheumatol"},{"key":"6190_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2011\/804296","volume":"2011","author":"T Frech","year":"2011","unstructured":"Frech T, Novak K, Revelo MP, Murtaugh M, Markewitz B, Hatton N et al (2011) Low-Dose Naltrexone for Pruritus in Systemic Sclerosis. Int J Rheumatol 2011:1\u20135. https:\/\/doi.org\/10.1155\/2011\/804296","journal-title":"Int J Rheumatol"},{"issue":"10038","key":"6190_CR19","doi-asserted-by":"publisher","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna D, Denton CP, Jahreis A, Van Laar JM, Frech TM, Anderson ME et al (2016) Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387(10038):2630\u20132640. https:\/\/doi.org\/10.1016\/S0140-6736(16)00232-4","journal-title":"Lancet"},{"issue":"1","key":"6190_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4103\/ijdd.ijdd_16_22","volume":"9","author":"A Singh","year":"2023","unstructured":"Singh A, Udayan UK, Tiwary PK, Prasad G, Jha AK, Md Z et al (2023) Efficacy and safety of rituximab in treatment of systemic sclerosis: A retrospective study. Indian J Drugs Dermatol 9(1):21\u201327. https:\/\/doi.org\/10.4103\/ijdd.ijdd_16_22","journal-title":"Indian J Drugs Dermatol"},{"issue":"9","key":"6190_CR21","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1093\/rheumatology\/kead012","volume":"62","author":"DJ Griffiths-Jones","year":"2023","unstructured":"Griffiths-Jones DJ, Garcia YS, Ryder WD, Pauling JD, Hall F, Lanyon P et al (2023) A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology 62(9):3133\u20133138. https:\/\/doi.org\/10.1093\/rheumatology\/kead012","journal-title":"Rheumatology"},{"issue":"1","key":"6190_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1159\/000438605","volume":"38","author":"A Baba","year":"2016","unstructured":"Baba A, Tachi M, Ejima Y, Endo Y, Toyama H, Matsubara M et al (2016) Anti-Allergic Drugs Tranilast and Ketotifen Dose-Dependently Exert Mast Cell-Stabilizing Properties. Cell Physiol Biochem 38(1):15\u201327. https:\/\/doi.org\/10.1159\/000438605","journal-title":"Cell Physiol Biochem"},{"issue":"3","key":"6190_CR23","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1002\/art.1780340315","volume":"34","author":"BL Gruber","year":"1991","unstructured":"Gruber BL, Kaufman LD (1991) A double-blind randomized controlled trial of ketotifen versus placebo in early diffuse scleroderma. Arthritis Rheum 34(3):362\u2013366. https:\/\/doi.org\/10.1002\/art.1780340315","journal-title":"Arthritis Rheum"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06190-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-026-06190-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-026-06190-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T07:17:24Z","timestamp":1784272644000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-026-06190-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":23,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["6190"],"URL":"https:\/\/doi.org\/10.1007\/s00296-026-06190-5","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"assertion":[{"value":"14 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None of the authors have a conflict of Interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"166"}}